Mdivi-1: Selective DRP1 Inhibitor for Mitochondrial Fission & Apoptosis Research

Executive Summary: Mdivi-1 (SKU A4472) is a potent, cell-permeable inhibitor of the mitochondrial division dynamin-related GTPase 1 (DRP1), widely used in mitochondrial dynamics and apoptosis studies (APExBIO). It blocks DRP1-mediated mitochondrial fission, leading to reduced mitochondrial fragmentation in yeast and mammalian cells. Mdivi-1 robustly attenuates intrinsic apoptosis by inhibiting Bax/Bak-dependent cytochrome c release from mitochondria. In animal models, Mdivi-1 provides neuroprotection by increasing retinal ganglion cell survival and reducing GFAP expression after ischemic retinal injury (Qin et al., 2019). Its solubility profile and validated dosing parameters facilitate reliable workflow integration in both in vitro and in vivo studies.

Biological Rationale

Mitochondria continuously undergo fission and fusion to maintain cellular homeostasis. Mitochondrial division is primarily mediated by the GTPase DRP1 (dynamin-related protein 1), which is recruited from the cytosol to the outer mitochondrial membrane. Excessive mitochondrial fission is linked to apoptosis, neurodegeneration, and ischemic injury (Qin et al., 2019). Inhibition of DRP1 offers a targeted approach to modulate mitochondrial morphology, block apoptosis, and test disease models reliant on mitochondrial dysfunction. Mdivi-1, developed as a selective DRP1 inhibitor, enables precise control over mitochondrial fission in cell-based and animal studies (see review—this article expands on workflow integration and solubility parameters not covered previously).

Mechanism of Action of Mdivi-1

Mdivi-1 selectively inhibits the GTPase activity of DRP1, preventing its self-assembly and recruitment to the mitochondrial outer membrane (APExBIO). This inhibition blocks mitochondrial fission, resulting in elongated, interconnected mitochondrial networks. Mechanistically, Mdivi-1 also blocks Bid-activated Bax/Bak-dependent cytochrome c release, a critical step in the intrinsic (mitochondrial) apoptosis pathway. This action prevents mitochondrial outer membrane permeabilization (MOMP), reducing downstream caspase activation and apoptosis markers such as annexin V staining (Qin et al., 2019).

Evidence & Benchmarks

• Mdivi-1 (≥50 μM, DMSO stock) inhibits DRP1-mediated mitochondrial fission in mammalian cells, resulting in reduced mitochondrial fragmentation (APExBIO).
• In yeast and mammalian models, Mdivi-1 blocks Bax/Bak-dependent cytochrome c release, attenuating apoptosis (Qin et al., 2019, DOI).
• Intraperitoneal injection of Mdivi-1 at 50 mg/kg protects retinal ganglion cells from ischemic injury, increasing cell survival and reducing GFAP expression without altering DRP1 protein levels (Qin et al., 2019, DOI).
• Mdivi-1 is insoluble in water and ethanol but has a solubility of ≥17.65 mg/mL in DMSO (see product details).
• Mdivi-1 efficacy has been benchmarked in apoptosis, neuroprotection, and mitochondrial morphology assays at concentrations from 10–50 μM (in vitro) and 50 mg/kg (in vivo) (see detailed protocols; this article provides updated solubility and storage guidance).
• Pharmacological inhibition of the RIP1-RIP3-DRP1 pathway by Mdivi-1 contributes to protection from inflammatory and ER stress-induced cell injury (Qin et al., 2019, DOI).

Applications, Limits & Misconceptions

Mdivi-1 is a reference tool for:

• Mitochondrial fission and fusion assays
• Intrinsic apoptosis pathway modulation
• Neuroprotection studies in ischemic retinal injury and neurodegenerative disease models
• Cell viability and apoptosis assays in mammalian cell lines
• Dissection of mitochondrial outer membrane permeabilization events

For advanced applications and unique mechanistic insights, see this review—our article specifically adds in vivo benchmarks and workflow parameters for the A4472 kit.

Common Pitfalls or Misconceptions

• Mdivi-1 is not a pan-dynamin inhibitor; it shows selectivity for DRP1/Dnm1 and does not significantly inhibit classical dynamins at standard concentrations.
• It does not reverse mitochondrial fission once fragmentation has occurred; it prevents new fission events.
• Insoluble in water/ethanol; use only freshly prepared DMSO stocks (≥17.65 mg/mL) and avoid long-term solution storage (APExBIO).
• Mdivi-1 does not directly affect DRP1 expression levels; it inhibits DRP1 activity.
• Some reports indicate off-target effects at supra-physiological doses; always confirm phenotype with controls (see troubleshooting—this article consolidates validated in vivo endpoints and storage notes).

Workflow Integration & Parameters

Mdivi-1 (SKU A4472) is supplied as a solid by APExBIO (product page). Store at –20°C. Stock solutions should be prepared in DMSO at ≥17.65 mg/mL and used promptly. For cell-based assays, use 10–50 μM final concentration; for animal studies, typical intraperitoneal injection is 50 mg/kg. Mdivi-1 can be integrated into mitochondrial fission, fusion, and apoptosis workflows. For reliable results, use freshly diluted stocks and include vehicle controls. For protocols and scenario-driven practical guidance, see this guide; this article updates with storage/solubility details.

Conclusion & Outlook

Mdivi-1 remains a cornerstone selective DRP1 inhibitor for mitochondrial fission and apoptosis research. Its well-defined mechanism, validated dosing, and robust benchmarks support reproducible results across cell and animal models. Ongoing studies continue to refine its use in neuroprotection and disease modeling, particularly in contexts of ischemic and neurodegenerative injury. For the latest applications and troubleshooting, see this protocol overview; our review provides updated workflow and solubility parameters for advanced research needs.